# The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students

> **NCT06208683** · PHASE4 · UNKNOWN · sponsor: **Sinovac Biotech Co., Ltd** · enrollment: 400 (actual)

## Conditions studied

- Mumps
- Influenza

## Interventions

- **BIOLOGICAL:** Mumps vaccine, Live (MV)
- **BIOLOGICAL:** Influenza Vaccine, inactivated, quadrivlent(QIV)

## Key facts

- **NCT ID:** NCT06208683
- **Lead sponsor:** Sinovac Biotech Co., Ltd
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-11-04
- **Primary completion:** 2024-02-02
- **Final completion:** 2024-12-01
- **Target enrollment:** 400 (ACTUAL)
- **Last updated:** 2024-01-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06208683

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06208683, "The Immunogenicity and Safety of the Booster Doses of a Live-attenuated Mumps Vaccine in Junior High School Students". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT06208683. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*